Skip to main content
Caplight Logo









Vaxdyn

Vaxdyn

Private
SevilleHealthcare & Life Scienceshttps://vaxdyn.com/

Last Round

Series A

Sep 7, 2026

Total Funding Raised

$38M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Vaxdyn is a biotechnology company that develops vaccines to prevent infections caused by drug-resistant bacteria.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

vaccine developmentAMRantimicrobial resistancesuperbug vaccinebiotechnologyprophylactic vaccinesdrug discoverybacterial infectionmulti-drug resistant bacteriapreclinical developmentbiotech startupvaccine pipelineinfectious diseasepharmaceutical R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vaxdyn Comparables

Compare Vaxdyn with similar companies based on industry and business-model similarity.

Vaxdyn comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Immunethep
86%
Eli Lilly and Company
83%
Omniose
82%

Vaxdyn Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 7, 2026
GrantSep 2, 2024
Series ASep 2, 2024
GrantApr 22, 2024
GrantDec 2, 2021
Seed
Mar 8, 2021

Key People

Founding team and executive leadership

Juan Jose Infante

CEO

Executive Team

Vaxdyn Investors

Notable investors and investment history

Vaxdyn investors
InvestorRounds
European Innovation Council FundSeries A, Grant
CARB-XGrant
Arcano PartnersSeries A
Biovance Capital PartnersSeries A
Bionova CapitalSeed
EIC FundSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 7, 2026

    $13M round led by Biovance Capital Partners.

  • Aug 21, 2026

    Monthly visitors increased 482% MoM, from 74 to 431.

Recent news

Latest coverage and updates

  • receives_financingSep 7, 2026

    Vaxdyn received financing of $12.8M in Series A on Sep 7th '26.

Vaxdyn Filings

Explore SEC and related filing metadata, where available.

Vaxdyn filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vaxdyn's valuation, stock price, and market status.

Is VAXDYN a public or private company?

VAXDYN is a private company.

What is the current stock price of VAXDYN?

VAXDYN is a private company with no public stock price. No recent secondary market data is available.

How much is VAXDYN worth (valuation)?

Valuation information for VAXDYN is not publicly available.

Can I buy VAXDYN stock?

VAXDYN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was VAXDYN's last funding round?

VAXDYN's most recent funding round was Grant on September 2, 2024.

Who are the main investors in VAXDYN?

Key investors in VAXDYN include EIC Fund.

Will VAXDYN IPO soon?

No public IPO plans have been announced for VAXDYN.

How can I track VAXDYN secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VAXDYN's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeville
Employee Range10
Year Founded2011
Last FundingSep 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?